---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013477"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:23:47.067823+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PAVmed completes $45M financing, eliminates convertible debt; Q4 net loss $1.8M

## Summary
- PAVmed completed $30M Series D preferred offering and $15M senior secured note, eliminating all outstanding convertible securities.
- GAAP net loss attributable to common stockholders $1.8M ($2.05 per share diluted); non-GAAP adjusted loss $0.9M ($1.05 per share).
- Lucid Diagnostics recognized $1.5M EsoGuard revenue in Q4 2025, processed 3,664 tests; awarded VA contract for ~9M veterans.
- Veris Health completed EHR integration with OSU James Cancer Hospital; targeting late 2026 FDA submission for implantable monitor.
- PAVmed appointed Joseph Virgilio as CBO of Medical Devices and licensed endoscopic esophageal imaging technology from Duke University.

## SEC filing metadata
- accession: 0001493152-26-013477
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/0001493152-26-013477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013477
- JSON: https://secwatch.observer/filing/0001493152-26-013477.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013477.txt

## Key facts
- Earnings Releases
  PAVmed Inc. reported financial results for year ended December 31, 2025.
  - Period: year ended December 31, 2025
  - Result: reported results
  source text: PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/0001493152-26-013477-index.htm
- Earnings Releases
  PAVmed Inc. reported three months ended December 31, 2025 results: net income approximately $1.8 million, EPS $(2.05) per common share on a diluted basis.
  - Period: three months ended December 31, 2025
  - Net income: approximately $1.8 million
  - EPS: $(2.05) per common share on a diluted basis
  - Result: reported results
  source text: For the three months ended December 31, 2025, Operating expenses were approximately $6.9 million which include stock-based compensation expenses of $0.3 million. GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/0001493152-26-013477-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.